PneumoNIX was selected as 1 of 15 MedTech start-ups to attend VentureWell’s investor readiness program. The program ensures the companies have a solidified go-to-market plan with planned milestones and a comprehensive due diligence deal room package. Furthermore, PneumoNIX secured partnerships to help with product launch and market adoption.
top of page
Recent Posts
See AllPneumoNIX has received follow-on Phase II grant from the NSF SBIR to continue the development of their proprietary technology.
180
PneumoNIX Medical, a Baltimore-based medtech company focused on preventing complications associated with soft tissue biopsies, announced that it received Phase I SBIR grants from the NSF. The awards w
40
PneumoNIX Medical was selected to present to Johns Hopkins Hospital, Maryland Department of Commerce and Technology Development Corporation of Maryland about their technology and its ability to increa
20
bottom of page